Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy

Phase 2

• Conditions: Peripheral Neuropathy
• Interventions: Drug: FOLFOX regimen; Drug: HD6610 Granule; Drug: HD6610 Granule placebo

• Registration Number: NCT02590367
• Lead Sponsor: Jiangsu Province Hospital of Traditional Chinese Medicine

Brief Summary

The purpose of this study is to estimate the usefulness and safety of HD6610 granule for oxaliplatin-induced peripheral neuropathy. The investigators examined the efficacy and safety of the treatment algorithm for 64 patients with colorectal cancer by evaluating the side effects and degree of improvement of subjective symptoms.

Detailed Description

Oxaliplatin is the third generation platinum-based cytotoxic agent, widely used in colorectal cancer, in metastatic disease and in the adjuvant setting . Moreover, oxaliplatin is being used as an alternative option to cisplatin in various cancers, such as ovarian, gastric. Oxaliplatin-induced peripheral neuropathy is characterised by acute and transient cold hyperaesthesia in the hours and days following oxaliplatin infusion (\>90% of patients), but also by retarded chronic neuropathy due to the repetition of chemotherapy cycles (30-50% of patients). Oxaliplatin-induced peripheral neuropathy impairs the health-related quality of life (HRQOL) of patients and no preventive or curative strategies have as yet proven effective so far. Animal experiment show that HD6610 granule can relieve mouse's peripheral neuropathy induced by oxaliplatin. In clinical practice, the investigators also find that HD6610 granule can relieve patient's oxaliplatin-induced peripheral neuropathy in the treatment of chemotherapy. So the investigators design this randomized, parallel-group, double-blind, placebo-controlled, multicenter clinical study to estimate the efficacy and safety of HD6610 granule for oxaliplatin-induced peripheral neuropathy in colorectal cancer.

Study Timeline

• Study Start: 2015-08
• Study First Submitted: 2015-09-14
• Study First Submitted QC: 2015-10-27
• Study First Posted: 2015-10-29
• Status Verified: 2015-11
• Last Update Submitted: 2015-11-30
• Last Update Posted: 2015-12-02
• Primary Completion: 2017-10
• Study Completion: 2017-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

1. All cases have been diagnosed with colorectal cancer by pathology;
2. Patients who received no chemotherapy before should receive oxaliplatin-based chemotherapy(FOLFOX4,FOLFOX6,XELOX) ;
3. Patients of 18-70 years old have no serious heart,liver,kidney and hematopoietic disfunction,life expectancy of over 3 months and KPS more than 60;
4. Patients with no positive sign in neurological examination,and no drug allergy history or diabetes;
5. Volunteered to participate and signed informed consent,patients can not receive radiotherapy,acupuncture and moxibustion or other treatment during the experiment.

Exclusion Criteria

1. Not accordant with the inclusion criteria;
2. Patients who have used herbal within 4 weeks before registration;
3. Patients who have serious heart,liver,kidney and hematopoietic disfunction;
4. Patients of central nervous system disease;
5. Patients of cervical spondylopathy,lumbar disc protrusion,diabetes and uremia which can potentially cause peripheral neuropathy;
6. Nerve compression caused by tumor metastasis or peripheral neuropathy caused by electrolyte disturbances,diabetes,alcohol disease and other disorder;
7. Long-time using of thiazide diuretic and foxglove;
8. Patients of poisoning,infection and radiotherapy which induced peripheral neuropathy or receiving medicine which can cause peripheral neuropathy;
9. Patients who can hardly take Chinese Medicine with severe diarrhea,vomiting or intestinal obstruction ;
10. Uncontrolled psychosis;
11. Women of pregnancy ,preparing pregnant, or lactation;
12. Alcohol and drug abuse;
13. Allergic constitution or allergy to experiment drugs.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
FOLFOX regimen&HD6610 Granule	HD6610 Granule	Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the HD6610 Granule will be given 2 times a day.
FOLFOX regimen&HD6610 Granule	FOLFOX regimen	Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the HD6610 Granule will be given 2 times a day.
FOLFOX regimen&HD6610 Granule placebo	FOLFOX regimen	Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the placebo HD6610 Granule
FOLFOX regimen&HD6610 Granule placebo	HD6610 Granule placebo	Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the placebo HD6610 Granule

Primary Outcome Measures

Name	Time	Method
The number of patients with different degree of peripheral nerve toxicity.	Through study completion, an average of 1 year.

Secondary Outcome Measures

Name	Time	Method
EORTC（European Organization for Research and Treatment of Cancer） quality of life score	Through study completion, an average of 1 year.
KPS（ Karnofsky Performance Status Scale） score	Through study completion, an average of 1 year.

Trial Locations

Locations (1)

Jiangsu Province Hospital of Integrated Chinese and Western Medicine; 🇨🇳 Nanjing, Jiangsu, China